Entering text into the input field will update the search result below

Inhibrx stock soars 33% on potential accelerated approval path for INBRX-101 after FDA discussions

Oct. 04, 2022 11:42 AM ETInhibrx, Inc. (INBX) StockBy: Ravikash Bakolia, SA News Editor

FDA written on wooden cube with keyboard , calculator, chart,glasses.Business concept

Iryna Drozd

Inhibrx (NASDAQ:INBX) stock rose ~33% on Oct. 4 after the company said there was potential to pursue an accelerated approval in the U.S. for INBRX-101 to treat a lung disorder, after discussions with the U.S. Food and Drug Administration (FDA).

Recommended For You

More Trending News

About INBX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
INBX--
Inhibrx, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.